This introductory 2-page document defines microbicides and reviews the state of research on some leading candidates.
Microbicides for HIV Prevention: An introductory factsheet
Multipurpose Prevention Technologies (MPTs): An introductory factsheet
This introductory 2-page document makes the case for why women need prevention options that protect them against multiple risks—HIV, STIs and/or pregnancy—and discusses the products that are being studied for this purpose. The factsheet is part of a series on emerging HIV prevention strategies.
Press Statement from Kenya AIDS Civil Society AIDS Groups Cheer First Major New Commitment by Presidential Candidate
This press release from a coalition of Kenyan civil society groups celebrates a success in an election-year campaign led by 2013 AVAC Advocacy Fellow Maureen Milanga to secure commitments to good HIV policy by political candidates. The pledge by Prime Minister Raila Odinga committed his administration, if elected, to provide universal access to antiretroviral therapy and to spend 15 percent of the national budget on healthcare.
Online CHAIN MSM Survey: Willingness and influencing factors for usage of PrEP among MSM
This study of 760 men who have sex with men in China, conducted by 2013 AVAC Advocacy Fellow Cai Lingping, finds high acceptability of pre-exposure prophylaxis. The survey also assessed how well informed respondents were about PrEP and examined factors that would make them more or less willing to take it.
HIV Civil Society Recommendations for Kenya’s New Health Secretary and Global Fund Application
This letter, written by a civil society coalition co-led by 2013 AVAC Advocacy Fellow Maureen Milanga, summarizes concerns and demands related to Kenya’s 2013 application to the Global Fund. The letter was sent during the Global Fund’s transition to its New Funding Model and includes guidance to the Government of Kenya on how to navigate the new system to secure support for ambitious treatment scale-up in the wake of new WHO treatment guidelines.
The Change We Need to End AIDS in Uganda: A civil society analysis of the state of Uganda’s AIDS response
This document, developed by a coalition of civil society groups co-led by AVAC Advocacy Fellows Alice Kayong-Mutebi, Richard Hasunira and Sylvia Nakasi, identifies failures in the Ugandan AIDS response and a 10-point plan to end the country’s epidemic.
Letter to Ambassador Goosby on PEPFAR and the national response to HIV in Uganda in 2012-13
This letter, written by a coalition of civil society groups co-led by AVAC Advocacy Fellows Alice Kayong-Mutebi, Richard Hasunira and Sylvia Nakasi, summarizes concerns and demands related to the US PEPFAR program’s 2012 Country Operating Plan. A country operating plan dictates the scope, funding levels and targets of PEPFAR programming on an annual basis.
Ugandan Service Provider Perspectives on the WHO Recommendation on Hormonal Contraceptives and HIV Risk
This abstract poster, developed by 2012 AVAC Advocacy Fellow Lydia Mulwanyi-Mukombe and her Host, Lillian Mworeko, describes key findings from consultations with Uganda service providers. It reports how providers were planning to use the new WHO guidance and makes recommendations for how to protect and inform women in light of the potential HIV risk associated with hormonal contraceptive use.
Community Involvement in HIV Prevention Research: Experiences and perceptions of communities participating in the MDP 301 microbicide trial in Masaka, Uganda
This case study by 2010 AVAC Advocacy Fellow Richard Hasunira assesses the community engagement efforts of the Masaka trial site through interviews with participants, trial staff, and other stakeholders. It highlights success that other trials should replicate and lessons learned from shortcomings.
MUWRP/AVAC: Biomedical HIV Prevention Research Stakeholder Training Resource
This manual, developed by 2010 AVAC Advocacy Fellow Jauhara Nanyondo, is an HIV prevention literacy tool intended to improve reporting by Ugandan media. It covers background information on HIV, provides an overview of existing and emerging prevention options, and discusses clinical research process and ethics.